STERLINBIO

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange has sought clarification from Sterling Biotech Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -3. Board meeting notice not submitted. The response of the Company is awaited.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

Sterling Biotech Limited has informed the Exchange regarding Outcome of the Meeting of Resolution Professional held on December 19, 2018.

Sterling Biotech Limited has informed the Exchange regarding 'Meeting of the Resolution Professional scheduled to be held on Wednesday, 19th December 2018 at 02.30 P.M. IST at C-25, Laxmi Towers, A �� 601, 6th Floor, Bandra Kurla Complex, Bandra (East), Mumbai 400051, INDIA'.

��The Exchange had sought clarification from the Company with respect to news item captioned- "Sterling Biotech case: Termed proceeds of money laundering Rs 4,701 cr assets attached ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has no

The Exchange has sought clarification from the Company with respect to news item captioned- "Sterling Biotech case: Termed proceeds of money laundering Rs 4,701 cr assets attached ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 �� Further Extension of One (1) Month given to Sterling Biotech Limited for holding its 32nd Annual General Meeting for the financial year ended 31st March 2018'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 - Extension of Corporate Insolvency Resolution Process of Sterling Biotech Limited by 90 days.'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

STERLINBIO:The Exchange had sought clarification from Sterling Biotech Limited with respect to announcement dated 02-Nov-2018, regarding " Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.".On basis of above the Company is required to clarify following:1. Any other material information not involving commercial secrets<br>2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified<br>3. Approval of res

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

STERLINBIO:The Exchange has sought clarification from Sterling Biotech Limited with respect to announcement dated 02-Nov-2018, regarding " Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets<br> 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified<br> 3. Approval o

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange had sought clarification from the Company with respect to news item captioned- " Delhi Court issues notices to Sterling Biotech owners in Rs 8,100 cr loan fraud case". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not be

STERLINBIO:The Exchange had sought clarification from Sterling Biotech Limited with respect to announcement dated 26-Oct-2018, regarding " Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.".On basis of above the Company is required to clarify following:1. Quantum of claims, if any<br>2. Expected financial implications, if any, due to compensation, penalty etc;<br>3. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Members of the Exchange are hereby informed that the Exchange on November 01, 2018 has issued public notice in the newspaper for proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).

STERLINBIO:The Exchange has sought clarification from Sterling Biotech Limited with respect to announcement dated 26-Oct-2018, regarding " Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.". On basis of above the Company is required to clarify following: 1. Quantum of claims, if any<br> 2. Expected financial implications, if any, due to compensation, penalty etc;<br> 3. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange has sought clarification from the Company with respect to news item captioned- " Delhi Court issues notices to Sterling Biotech owners in Rs 8,100 cr loan fraud case". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not be

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange has sought clarification from the Company with respect to news item captioned- " ED to seek fugitive economic offender tag for 4 accused in Sterling Biotech case". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been a

The Exchange had sought clarification from the Company with respect to news item captioned- " ED files chargesheet against 191 entities ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regula

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange has sought clarification from the Company with respect to news item captioned- " ED files chargesheet against 191 entities ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regula

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding�� Extension of Two (2) Months given to Sterling Biotech Limited for holding its Annual General Meeting for the financial year ended March 31, 2018'.

The Exchange had sought clarification from the Company with respect to news item captioned- Promoters of Vadodara based Sterling Biotech offered Rs.3000 crores as settlement to consortium of banks against Rs.5400 crores bank loan scam.The response from the Company is attached.

The Exchange had sought clarification from the Company with respect to news item captioned- Bank loan fraud: ED to file charge sheet against Sterling Biotech promoters. The response from the Company is attached.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange has sought clarification from the Company with respect to news item captioned- Promoters of Vadodara based Sterling Biotech offered Rs.3000 crores as settlement to consortium of banks against Rs.5400 crores bank loan scam.In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of

The Exchange has sought clarification from the Company with respect to news item captioned- Bank loan fraud: ED to file charge sheet against Sterling Biotech promoters. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any in

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange had sought clarification from the Company with respect to news item captioned- Rs 50-bn scam: Sterling Biotech director Nitin Sandesara held in Dubai. The response from the Company is attached

The Exchange has sought clarification from the Company with respect to news item captioned- Rs 50-bn scam: Sterling Biotech director Nitin Sandesara held in DubaiIn this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any informati

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange had sought clarification from the Company with respect to news item captioned- ED charge sheet against Sterlite Biotech director. The response from the Company is attached.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.